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Abstract—Sepsis, a life-threatening illness, is estimated to be
the primary cause of death for 50,000 people a year in the
UK and many more worldwide. Managing the treatment of
sepsis is very challenging as it is frequently missed at an early
stage and the optimal treatment is not yet clear. There are
promising attempts to use Reinforcement Learning (RL) to learn
optimal strategies to treat sepsis patients, especially for the
administration of intravenous fluids and vasopressors. However,
some RL agents only take the current state of patients into
account when recommending the dosage of vasopressors. This
is inconsistent with clinical safety practice in which the dosage
of vasopressors is increased or decreased gradually. A sudden
major change of the dosage might cause significant harm to
patients and as such is considered unsafe in sepsis treatment.
In this paper, we have adapted one of the deep RL methods
published previously and evaluated whether the learned policy
contains these sudden, major changes when recommending the
vasopressor dosage. Then, we have modified this method to
address the above safety constraint and learnt a safer policy
by incorporating current clinical knowledge and practice.
Index Terms—Sepsis treatment, Reinforcement learning, Safe
policy
I. INTRODUCTION
Sepsis is a life-threatening organ dysfunction caused by a
dysregulated host response to infection [1]. A recent estimation
is that one in five deaths worldwide is caused by sepsis [2]
[3]. A major challenge is early detection of sepsis since the
earlier the treatment begins the greater the chance of patient
recovery. Once the condition has been detected, treatment
normally involves administration of antibiotics and infection
source control. When it turns into septic shock, administration
of intravenous fluids and vasopressors will be necessary, but
deciding on the treatment strategy for intravenous fluids and
vasopressors is often difficult. Different fluid and vasopressor
treatment strategies have been tested leading to quite different
results in terms of patient mortality [4]. Further, many health-
care agencies and communities have devoted significant efforts
to sepsis management, e.g. the Surviving Sepsis Campaign [5].
This project is funded by Bradford Teaching Hospitals NHS Foundation
Trust and supported by Assuring Autonomy International Programme.
Despite such efforts, the optimal strategy for the administration
of intravenous fluids and vasopressors remains unclear.
Some research groups have harnessed Reinforcement Learn-
ing (RL) to learn optimal strategies for recommending intra-
venous fluids and vasopressors. For example, the AI Clinician
[6] has been developed using RL to dynamically recommend
fluids and vasopressors for adult patients. RL is a very power-
ful machine learning (ML) technique which is widely used in
complex decision making tasks to find an optimal policy [7].
It assumes that the environment can be viewed as a Markov
Decision Process (MDP) in which an assumption is made that
the future state of the process depends only on the current
state; that is, given the current state, the future state does not
depend on the cumulative history of past states.
However, for a complex intervention to be safe and effective,
it is important for the technology to fit with accepted clinical
practices and workflows. In the case of sepsis treatment, when
recommending dosage for vasopressors, if we merely consider
the optimal action based on the current state, it might cause a
sudden major change in the dosage, which can be dangerous to
some patients, e.g. resulting in acute hypotension (arising from
rapidly decreasing doses), hypertension or cardiac arrhythmias
(arising from rapidly increasing doses) [8] [9] [10]. Because
the half life (the period of time for the concentration of
a drug in the body to reduce by 50%) of Norepinephrine
(a commonly used vasopressor) is measured in seconds or
minutes [11], changes in Norepinephrine can have rapid effects
on patients. The recommended dosage (and dosage changes)
for intravenous fluids is less sensitive than for vasopressors as
the half life of fluids is measured in hours [12], thus changes
in fluid take a lot longer to take effect. Therefore, in this work,
we focused on the safety of vasopressor administration.
In this paper, we have adapted a previously published deep
RL method [13] used to learn the optimal treatment strategy,
or policy, to investigate further the safety issues associated
with sepsis treatment. The data used for learning the optimal
policy is a large publicly available database - MIMIC III
[14], collected from USA hospitals. As the MIMIC III data
set was generated by recording the real clinicians’ actions,
we refer to it as the clinician policy in comparison with
the learnt optimal policy. We evaluated the learnt optimal
policy and compared it against the clinician policy, i.e. the
real patient trajectories in the test data set, including whether
or not they show this kind of sudden major change when
recommending vasopressor dosage for each patient. In doing
so we identified that the learnt optimal policy has many more
sudden major dosage changes than the clinician policy. As
a consequence, we modified the model to capture the change
between the current vasopressor dose and previous vasopressor
dose in the state space. In addition, we modified the RL cost
function to penalise the policy when this kind of behaviour is
learnt. The result shows that what we have learnt has fewer
sudden major changes and is therefore closer to the clinician’s
behaviour. Finally, we have evaluated both policies using
a regression-based procedure for off-policy evaluation [15],
which shows that the performance of our modified policy has
higher value than the clinician policy. However, although the
learnt optimal policy based on [13] seems to have higher value
than our modified policy, in terms of vasopressor delivery, our
modified policy is safer in the sense of being consistent with
clinicians’ knowledge, specifically in terms of avoiding sudden
vasopressor changes and their harmful effects.
II. BACKGROUND
RL consists of an agent interacting with its environment by
producing actions and discovering errors or receiving rewards
[7]. The environment is often represented by an MDP. An
MDP is defined by M = 〈S,A, P,R, γ〉, where S is the
state space, A is the action space, P is the transition function
with P (s′|s, a) denoting the probability of reaching state s′
if taking action a in state s. R is the reward function with
R(s, a) being the expected immediate goodness of (s, a) and
γ is the discount factor. A policy fully defines the agent’s
behaviour and maps the perceived states of the environment
to actions for the agent to take. It is often denoted as pi. If
the agent is following policy pi at time t, then pi(a|s) will
be the probability that At = a if St = s. The action-value
function Qpi(s, a) = Epi
[∑T
t′=t γ
t′−trt′ |St = s,At = a
]
, is
the expected discounted reward starting from state s, taking
action a, when following policy pi, where rt is the reward
received when transitions from the state st to the state st+1
after taking action at and has mean R(st, at) conditioned on
(st, at), and T is the terminal time step.
A deep Q-Network (DQN) is a widely-used modern RL
algorithm, which combines Q-learning [16] with a deep arti-
ficial Neural Network (NN) [17]. It learns the optimal policy
by employing the same update rules and operating principles
as Q-learning but using an NN as its action function repre-
sentation. DQN uses the experiences or samples 〈s, a, r, s′〉
generated by interaction with the environment to train the NN.
It uses a squared error loss function, which is the difference
between the output of the network, Q(s, a, θ) and the desired
target Qtarget = r + γ maxa′Q(s
′, a′, θ) to update the NN.
The parameters θ of the NN are updated as follows:
θk+1 ← θk − α∇E[(Qtarget −Q(s, a; θ))
2], (1)
where k is the iteration step when training the NN. Simple
DQNs have some shortcomings and there are various ways
of refining them to improve their performance. One way to
improve them is to use double DQNs which employ two NNs,
one produced as in standard DQN, which is the main network
with parameters θ, and the other a copy of the network from
the last iteration used to obtain the Q-value, which is the target
network with parameters θ′. The standard double Q-network
loss is shown in (2).
L(θ) = E[(Qdouble−target −Q(s, a; θ))
2], (2)
where Qdouble−target = r+ γQ(s
′, argmaxa′Q(s
′, a′; θ); θ′).
In this work, we extended this equation to include a term
which accounts for safety (see section IV).
III. RELATED WORK
Much previous work in identifying the best treatment
for sepsis patients has focused on clinical trials. In [18]
they carried out a random trial to investigate the effect of
the discontinuation of vasopressors in management of septic
shock and found that tapering Norepinephrine rather than
Vasopressin may be associated with a higher incidence of
hypotension in patients recovering from septic shock who are
on concomitant Norepinephrine and Vasopressin. However, the
study was stopped early due to a significant difference in the
incidence of hypotension between the control and experimental
group, which also reveals the difficulty of conducting clinical
trials to find the optimal treatment for sepsis patients. A recent
review found that, in the last decade, the physiopathology of
sepsis has become better understood. However, it concluded
that clinical trials had yielded no satisfactory results [19].
More recently, researchers have utilised RL to learn the
optimal treatment for sepsis patients. The application of an
RL approach could reduce the time and cost to identify good
treatment strategies by finding new insights in large patient-
related clinical data sets, compared with clinical trials. For ex-
ample, the AI Clinician [6] was built using RL on the MIMIC
III database to explore the optimal treatment strategy for
administering intravenous fluids and vasopressors. The state
space included patients’ demographics, Elixhauser premorbid
status, vital signs, laboratory values, fluids and vasopressors
received. The action space for the MDP is discretised into 25
possible actions with 5 possible choices for intravenous fluids
and vasopressors respectively. This work used policy iteration
to find an optimal policy. The group have also applied double
DQN to determine the optimal policy, where they learned the
treatment policy over continuous spaces using an NN with
the same 25 actions [13]. They used SOFA (Sequential Organ
Failure Assessment) score and Arterial Lactate (the level of
lactate from arterial blood) to determine the intermediate
reward and a terminal reward of +15 or -15 depending whether
or not the patient survived their stay in hospital. The SOFA
score is a measurement of organ failure with high values
associated with poor outcome; similarly, high levels of lactate
are associated with poor outcomes in sepsis treatment. In detail
the intermediate reward function is:
r(st, st + 1) = C01 (s
SOFA
t+1 = s
SOFA
t & s
SOFA
t+1 > 0)+
C1(s
SOFA
t+1 − s
SOFA
t + C2 tanh(s
Lactate
t+1 − s
Lactate
t )
(3)
In this work, we have adapted the methods in [13] to
train an agent to learn the optimal policy based on the same
data set and the same patient cohort taken from MIMIC III
and used this as a basis for evaluating and enhancing our
approach. The patient cohorts are defined based on the sepsis-
3 criteria – suspected infections combined with SOFA score
≥ 2. Patients who satisfy the sepsis-3 criteria, but with any one
of the following conditions, 1. not adult, 2. intravenous fluid
intake not documented, 3. possible withdrawal of treatment, 4.
erroneous intake or output data, were excluded. The resulting
patient cohorts were divided into a training dataset (80%,
20938), a validation dataset (10%, 2149) and a testing dataset
(10%, 2160). For detailed patient features included in the state
space, see the supplement to [6].
IV. METHOD AND RESULTS
For ease of presentation, we combine the description of our
method and the results of the work.
A. Evaluation of the learned optimal policy
First, we have adapted the method in [13] to train the
agent to learn the optimal policy. The main adaptation was
considering 90-day mortality rather than deaths in hospital,
as some patients might choose to be discharged in order to
return home when they are unlikely to survive, so this is
more appropriate when learning the optimal policy. We also
used 47 features to represent the state space (as against 48
in the original work [13]) as one of the features is the time-
steps to treat the patient, and we believe this is less relevant
when clinicians are treating patients in reality, as they would
not decide to stop treating the patient just because they have
been treating the patient for a long period of time. Indeed,
they have also made this kind of alterations in their later
work [6]. The action space includes 25 possible actions with
five discretised choices for the dose of intravenous fluids and
five for vasopressors respectively, which is shown in Table I.
Table I also shows the detailed dose range and dose median
for the five vasopressor choices; this is important as this
work is focused on the safety of vasopressor administration.
Note that vasopressor dosage is shown in mcg/kg/min of
Norepinephrine equivalent. Fig. 1 shows the comparison of
the clinician policy and the learnt optimal policy on the test
data set. As can be seen, the clinicians tended to prescribe less
vasopressors and more intravenous fluids to patients than the
learnt optimal policy (note the high frequencies in the clinician
policy – 0,5,10,15,20 correspond to zero vasopressor dose).
The proportion of time the clinicians prescribed vasopressors
to patients was only 15% compared to 38% if the optimal
policy recommendation was followed.
Fig. 1. Action frequency over all patient trajectories in test data set, where
all actions are aggregated recommended by the clinician and optimal policies.
The results of this revision were generally consistent with
the AI Clinician [6] and [13] in that the learnt optimal policy
recommended more vasopressor than the clinicians’ policy.
Fig. 2 shows the correlations between the observed patient
mortality and the difference between the doses suggested
by the learnt optimal policy and the actual doses given by
clinicians (i.e. the clinician policy). It shows that the minimum
mortality rate is observed when there is no difference between
the optimal policy and the clinician policy, which means
patients who received doses similar to the doses recommended
by the optimal policy have the lowest mortality. This implies
that the learnt optimal policy is effective, which is the same
as indicated in [13].
Fig. 2. Observed mortality rate variation with the difference between the
doses recommended by the optimal policy and the actual doses, calculated by
considering 90-day mortality.
Based on this comparison, the policy we have learnt can
be seen to be similar to that in [13] in terms of optimality
and validity. However, in contrast to [13], we have evaluated
this policy from the safety perspective, specifically in terms
of sudden changes in the recommended vasopressor dosage.
According to [20], doses of Norepinephrine over 0.5
mcg/kg/min are usually considered to be “high” and suggest
the need for rescue or second-line therapy. Doses over 1.0
mcg/kg/min are rarely used. In the action space, shown in table
I, the maximum dose change occurs when the recommendation
changes from action 0 to action 4 in the following step for
the same patient, or vice versa. This change is 0 to 0.786
TABLE I
DOSAGE ACTIONS
Dose of vasopressor (mcg/kg/min)
No.: 0 1 2 3 4
Range: 0 (0.002, 0.079) (0.08, 0.2) (0.201,0.449) (0.45, 1.005)
Median: 0 0.04 0.135 0.27 0.786
Dose 0 0 1 2 3 4
of 1 5 6 7 8 9
IV 2 10 11 12 13 14
fluid 3 15 16 17 18 19
4 20 21 22 23 24
mcg/kg/min as 0.786 mcg/kg/min is the median of the fourth
quartile and is clearly in a dangerous range.
We evaluated the maximum vasopressor dose change for
the clinician policy and the learnt optimal policy on the test
data set, which has 2,160 patients, by calculating the max
absolute vasopressor dose change in one step for each patient
during their treatment. In the clinician policy, we found 2.6%
(57 patients) among 2,160 patients have this maximum dose
change – 0.786 mcg/kg/min. In contrast, in the learnt optimal
policy, we found 35% (756 patients) among 2,160 patients
have this sudden change. Fig. 3 shows the comparison of max
absolute vasopressor dose change between the clinician policy
and the learnt optimal policy for these 2,160 patients. The
max absolute vasopressor dose change following the learnt
optimal policy is substantially higher than that of following the
clinician policy. Further, many of the max absolute vasopressor
dose changes in the learnt optimal policy reach 0.786, while
there are only a few patients whose max absolute vasopressor
dose change reaches 0.786 in the clinician policy. This implies
that the learnt optimal policy may not be safe if used for
treating sepsis patients, because of the prevalence of these
sudden major dose changes and its harmful clinical effect.
Fig. 3, also shows that there are a lot of patients whose max
absolute vasopressor dose change was zero in the test data set
(i.e. following the clinician policy). This is consistent with Fig.
1 in that clinicians tended to give less vasopressors, so some
patients never got any vasopressors. However, if the learnt
optimal policy was followed, many more patients would move
out of the zero vasopressor “bucket”. This also indicates that
the learnt optimal policy tends to give more vasopressor to the
patients than the clinician policy does. The apparent “noise” in
Fig. 3 arises because the patients are sorted (ordered) first by
the maximum change in the test data (i.e. the clinician policy),
then by the maximum change in the optimal policy and, for
some patients, the clinician policy gave a higher maximum
change than the optimal policy.
B. Modification of the learnt optimal policy
In response to the above clinical safety concerns, we have
modified the model to embrace the safety constraint, which
is to reduce the rate of sudden major vasopressor dose
changes, particularly to avoid the maximum change of 0.786
mcg/kg/min. We made two alterations to enable the agent to
learn a safer policy.
Fig. 3. Comparison of max absolute vasopressor dose change in one step for
each patient in the test data set between the clinician and the learnt optimal
policy.
Firstly, we added an extra feature in the state feature space,
which is the relative dose change compared with the previous
vasopressor dose for each patient. This enables the agent to
take account of the difference between the current step and
the previous step in terms of vasopressor dose while learning
the optimal policy, rather than merely using the current step
state features.
Secondly, we have also altered the cost function used for
training. In [13], the authors added a regularisation term to the
standard double Q-network loss (see equation (2)) to penalise
output Q-values when it was outside the allowed thresholds
(|Qthresh| = 20). On this basis, we have added a second
regularisation term to penalise the output Q-values when the
recommended dose is higher or lower than the previous dose
by 0.786 mcg/kg/min (i.e., a jump from action 0 to action 4 or
vice versa in one step when recommending vasopressor doses
for the patients). The altered loss function is as follows:
L(θ) = E[(Qdouble−target −Q(s, a; θ))
2] + λ1max
(|Q(s, a; θ)| −Qthresh, 0) + λ2max(|Vchange| − 0.75, 0)
(4)
Vchange is the agent recommended dose (argmax of Q(s, a; θ))
minus the vasopressor dose in the previous step.
After the implementation of these two alterations we have
learnt a new modified policy. Fig. 4 shows the comparison of
the clinician policy and the learnt modified policy on the test
data set. It shows that the modified policy also recommends
more vasopressor than the clinician policy. However, in con-
trast to the learnt optimal policy in Fig. 1, the proportion of
time the modified policy recommended vasopressor to patients
was 24% compared to 38% in the learnt optimal policy.
Fig. 5 shows the relationship between observed mortal-
ity and the difference between the modified policy and the
clinician policy, which also shows that when there is no
difference between the modified policy and the clinician policy
the observed mortality is reduced to a minimum. This also
implies the validity of the modified policy.
Fig. 4. Action frequency over all patient trajectories in test data set, where all
actions are aggregated recommended by the clinician and modified policies.
Fig. 5. Observed mortality rate variation with the difference between the
doses recommended by the modified policy and the actual doses, calculated
by considering 90-day mortality.
Having made these modifications we evaluated the new
modified policy on the test data set to assess how many patients
are subject to the sudden major change of vasopressor dosage,
i.e. 0.786 mcg/kg/min. In total there are 7.87% (170 patients)
amongst the 2,160 patients found with this change. Thus, the
modified policy has reduced the rate of such sudden major
changes of vasopressor dose by 77.5% when compared with
the previous learnt optimal policy. Fig. 6 shows the maximum
absolute vasopressor dose change in one step for each patient
between the clinician policy and the modified policy. It shows
a clear reduction in sudden major dose changes and the
absolute change is much more reasonable compared to Fig. 3.
However, it also shows an overall increase in the recommended
vasopressor dose by comparison with the clinician policy,
but the recommendations are much smoother. This is also
consistent with the previous findings that it might be better
to administer more vasopressor for sepsis patients but this
modified policy behaves in a much safer way and is more
consistent with clinical reality.
Fig. 6. Comparison of max absolute vasopressor dose change in one step for
each patient in the test data set between the clinician and the modified policy.
Fig. 7. Feature importance (from out of bag score) for clinician policy and
the modified policy
In order to further assess the interpretability of the modified
policy, we built classification random forest models to under-
stand the relative importance assigned to the features in the
state space when recommending vasopressor. Then, we com-
pared the results with those of the clinician policy, see Fig.7.
For both random forest models (clinician and modified policy),
the current dose of vasopressor was discarded as the concern
here is on what features influence whether or not vasopressor
is recommended, not the size of the recommended dose. The
relative importance of each feature was estimated using an
out-of-bag score on the whole dataset, while we permuted the
values of each predictor, i.e. permutation feature importance
[21]. In both policies, SOFA plays the most important role,
which is as expected as SOFA describes sepsis-related organ
failure. Shock index is also among the top rankings as it
has been shown to indicate the need for vasopressor therapy.
Gender and re-admission in both polices shows the least
importance as these parameters are expected not to affect the
decision of whether recommending vasopressor or not. This
confirmed that the decisions suggested by the modified policy
were clinically interpretable and relied primarily on sensible
clinical parameters, such as SOFA, shock index, mean blood
pressure, or white blood cells count (WBC count) as shown
in the figure.
C. Performance evaluation
It is not feasible to evaluate the policy on real patients
because of ethical, legal and risk issues. Instead, we have
carried out off-policy evaluation to assess the performance of
the initial learnt optimal policy and the modified policy by
fitting an MDP model M̂ from the current data to approxi-
mate the environment. Then the value function is computed
using the estimated parameter transition probability P̂ and the
reward R̂ recursively. The final estimated value averaged the
resulting value function across all the observed trajectories in
the test data set (refer to [15] [22] for a detailed description
of the method). The average discounted reward of the chosen
actions under the clinician policy across all of the trajectories
in the test data set is also calculated as the benchmark, as
shown in table II. It shows that the learnt optimal policy has a
higher value than our modified policy. However, our modified
policy is still higher than the clinician policy and in terms of
vasopressor delivery, it is safer in the sense of avoiding sudden
vasopressor changes and its dangerous effects on patients.
TABLE II
PERFORMANCE COMPARISON FOR DIFFERENT POLICIES
Policy Estimated Discounted Reward
Clinician policy 7.16
Optimal policy 10.9
Modified policy 8.07
V. DISCUSSION
Effective treatment of sepsis is extremely important as it is
one of the major causes of fatalities in hospitals. As noted
above, clinical trials are expensive and are unlikely to identify
effective treatment strategies quickly [19]. ML methods, such
as RL, applied to clinical data have the potential to identify
good treatment strategies more cost-effectively, but there are
some potential pitfalls of ML which can give rise to unsafe
outcomes, and some challenges in introducing ML into a
clinical context.
First, the policies learnt in this case are produced by
optimising the cost function. The cost function used in [13]
does not address the rate of change of delivering vasopressor
which is known to be potentially hazardous. The approach
we have taken here enriches the cost function to take into
account this important factor in clinical safety. There may
be other factors that could beneficially be taken into account
in identifying optimal treatment policies thus it is vital to
combine knowledge of ML with clinical and patient safety
expertise.
Second, if ML-based approaches are to be used in practice,
in clinical settings, then it is necessary to assess their safety
prior to deployment. A key element is to assure the safety of
the ML-based system, potentially by producing a safety case
[23] dealing with the specific challenges of ML, as illustrated
in [24]. A second element is to engage with the clinicians in
such a way that they are able to trust the recommendations
produced by the system and are thus willing to use it in
practice. We will address both these issues in conjunction
with the team who developed the AI Clinician as part of the
Assuring Autonomy International Programme [25].
Third, in settings as complex as sepsis care it is unrealistic
to think that any treatment strategy learnt from historical
clinical data will be “perfect” and also stable over time. Thus,
it is important to learn from the behaviour of the system
as observed, as opposed to the behaviour we anticipated
(imagined), and to update our knowledge about the system as
it evolves. The framework presented in [24] is intended to give
a basis for monitoring and evaluating such complex systems
to reflect the evolution of the system and its environment, and
may therefore be helpful in this context.
VI. CONCLUSIONS
The work reported here illustrates both the potential value
of ML in clinical settings, especially where clinical trials are
costly and time-consuming, and the potential pitfalls of using
ML to recommend treatment strategies. We have shown how to
enrich the learning process with additional information about
the safety of the treatment strategy and this is an important
step forward in understanding how to integrate the notion of
patient safety into the ML process. Further work will consider
whether or not the learning process needs to be enriched
further, taking into account other clinically relevant factors.
It will also address the key challenge of assuring that the
system is acceptably safe to use, prior to deployment, and how
safety can continue to be improved by refining the treatment
strategies in use.
The code for learning the modified policy and for pro-
ducing the figures shown in the paper is available at:
https://github.com/Yanjiayork/sepsisRL.
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